The audit of company’s Telengana units has been completed today by the USFDA with four observations which will be addressed comprehensively within stipulated time.
At 15:26 hrs Dr Reddy’s Laboratories was quoting at Rs 2,155.10, down Rs 28.10, or 1.29 percent on the BSE.
The share touched its 52-week high Rs 2,788.00 and 52-week low Rs 1,901.65 on 24 July, 2017 and 11 August, 2017, respectively.
Currently, it is trading 22.7 percent below its 52-week high and 13.33 percent above its 52-week low.